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Abstract
Interleukin (IL)-6-mediated signaling attenuates the anti-myeloma activity of glucocorticoids
(GCs). We therefore sought to evaluate whether CNTO 328, an anti-IL-6 monoclonal antibody in
clinical development, could enhance the apoptotic activity of dexamethasone (dex) in pre-clinical
models of myeloma. CNTO 328 potently increased the cytotoxicity of dex in IL-6-dependent and
–independent human myeloma cell lines (HMCLs), including a bortezomib-resistant HMCL.
Isobologram analysis revealed that the CNTO 328/dex combination was highly synergistic.
Addition of bortezomib to CNTO 328/dex further enhanced the cytotoxicity of the combination.
Experiments with pharmacologic inhibitors revealed a role for the p44/42 mitogen-activated
protein kinase pathway in IL-6-mediated GC resistance. Although CNTO 328 alone induced
minimal cell death, it potentiated dex-mediated apoptosis, as evidenced by increased activation of
caspases-8, -9, and -3, Annexin-V staining, and DNA fragmentation. The ability of CNTO 328 to
sensitize HMCLs to dex-mediated apoptosis was preserved in the presence of human bone marrow
stromal cells. Importantly, the increased activity of the combination was also seen in plasma cells
from patients with GC-resistant myeloma. Taken together, our data provide a strong rationale for
the clinical development of the CNTO 328/dex regimen for patients with myeloma.
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The activity of glucocorticoids (GCs) for the treatment of multiple myeloma is well
established (Salmon, et al 1967). Although patient outcomes have improved with the advent
of novel agents, such as the immunomodulatory drugs, thalidomide and lenalidomide, and
the proteasome inhibitor bortezomib, GCs remain an important component of multi-agent
chemotherapy for newly-diagnosed and relapsed/refractory multiple myeloma (Dimopoulos,
et al 2007, Harousseau, et al 2006, Jagannath, et al 2005, Rajkumar, et al 2005, Rajkumar,
et al 2008b, Weber, et al 2007). However, resistance to GCs is a problem, as evidenced by
response rates to single-agent dexamethasone (dex) in clinical trials that ranged from 43% to
46% in newly-diagnosed myeloma, and 18% to 24% in relapsed and/or refractory disease
(Alexanian, et al 1992, Dimopoulos, et al 2007, Rajkumar, et al 2008b, Richardson, et al
2005, Weber, et al 2007). Furthermore, higher doses of GCs have been associated with
significant toxicity when given in combination with the immunomodulatory agents
(Rajkumar, et al 2008a). Development of therapeutics that overcome known mechanisms of
GC resistance is therefore a critical step to improving the efficacy of GC-containing
myeloma therapy and allowing the use of lower, more tolerable doses of GCs in
combination with newer regimens.
Interleukin (IL)-6 has been shown to enhance the proliferation and survival of myeloma
cells, both in suspension and in the presence of bone marrow stromal cells (Anderson, et al
1989, Kawano, et al 1988, Klein, et al 1989, Uchiyama, et al 1993), and to protect them
from apoptosis induced by GCs (Chauhan, et al 1997, Hardin, et al 1994, Juge-Morineau, et
al 1995, Lichtenstein, et al 1995, Rowley, et al 2000). IL-6 abrogated dex-mediated
cytotoxicity in part by activating and recruiting the protein tyrosine phosphatase SHP2 to
related adhesion focal tyrosine kinase (RAFTK), thereby interfering with dex-induced
activation of RAFTK and subsequent apoptosis (Chauhan, et al 1999, Chauhan, et al 2000).
Although the phosphatidylinositol (PI)-3 kinase-Akt signaling pathway has been implicated
as a crucial mediator of IL-6-induced GC resistance (Hideshima, et al 2001a), others have
shown that additional pathways, including the Ras-p44/42 mitogen activated protein kinase
(MAPK) pathway, are likely involved as well (Hsu, et al 2002, Ogawa, et al 2000).
Several growth factor pathways have been shown to confer GC resistance, including other
gp 130 family cytokines (Juge-Morineau, et al 1995), insulin-like growth factor-1 (Xu, et al
1997), interferon-alpha (Ferlin-Bezombes, et al 1998, Liu, et al 1999), B-cell activating
factor, a proliferation-inducing ligand (Moreaux, et al 2004), plasma cell (PC) cell-derived
growth factor (Wang, et al 2006), and fibroblast growth factor receptor-3 (Pollett, et al
2002). Mouse xenograft models of human myeloma and myeloma cell line/bone marrow
stromal cell (BMSC) co-culture experiments revealed, however, that IL-6 remains an
important GC resistance factor within the bone marrow microenvironment (Cheung and Van
Ness 2001, Grigorieva, et al 1998, Honemann, et al 2001, Tassone, et al 2005). We
therefore sought to determine whether inhibition of IL-6 signaling with CNTO 328, a
chimeric monoclonal antibody with high affinity for human IL-6 currently in clinical
development, would enhance the activity of GCs in pre-clinical models of myeloma.
Materials and Methods
Materials
Stock solutions of bortezomib (Millennium Pharmaceuticals; Cambridge, MA), LY294002,
and U0126 (Sigma-Aldrich; St. Louis, MO) were prepared in DMSO, stored at −20°C, and
diluted in culture media immediately before use. Dexamethasone (Sigma-Aldrich) was
prepared in 100% ethanol, stored at −20°C, and diluted in culture media immediately before
use. F105, an isotype control antibody that recognizes the CD4 binding site of HIV type 1
Voorhees et al. Page 2













gp120, and CNTO 328 were provided by Centocor, Inc. (Horsham, PA), and prepared in
0.15 M sodium chloride and 0.01 M sodium phosphate, pH 7.2. Final vehicle concentrations
did not exceed 0.5% (v/v).
Human myeloma cell lines, bone marrow stromal cultures, and patient myeloma samples
The human myeloma cell lines (HMCLs), ANBL-6, KAS-6/1, and MM1.S were provided
by Dr. Beverly Mitchell (Stanford University, CA), Dr. Diane Jelinek (Mayo Clinic, MN),
and Dr. William Dalton (H. Lee Moffitt Cancer Center, FL), respectively. H-929, RPMI
8226, and U266 HMCLs were obtained from the American Type Culture Collection
(Rockville, MD). HMCLs were grown in RPMI 1640 media (Gibco BRL; Grand Island,
NY) with 10% fetal bovine serum (FBS, Sigma-Aldrich). IL-6-dependent HMCLs and
myeloma patient samples were supplemented with 1 ng/ml of recombinant human IL-6 (R &
D Systems; Minneapolis, MN). Plasma cells from patients with myeloma and BMSC
cultures were established and cultured as previously described (Voorhees, et al 2007).
BMSCs and patient-derived myeloma samples were obtained under University of North
Carolina at Chapel Hill Institutional Review Board-approved protocols, and informed
consent was obtained in accordance with the Declaration of Helsinki.
Cell Viability Assays
Cell viability was measured using the cell proliferation reagent WST-1 per the
manufacturer’s protocol (Roche Applied Science; Indianapolis, IN) as previously described
(Voorhees, et al 2007). Cell viability was determined using the following equation: (OD of
drug-treated cells/OD control cells)*100.
Cell Death Assays
Activation of cell death was assessed via Annexin-V staining and DNA fragmentation as
previously described (Voorhees, et al 2007). 2×105 myeloma cells were seeded onto 4×104
BMSCs 24 hours prior to treatment for BMSC/myeloma cell co-culture experiments.
Activation of caspases-3, -8, and -9 was evaluated as previously described (Voorhees, et al
2007). Percent drug-specific apoptosis (Annexin-V staining and caspase-3 activation) was
calculated using the following formula: [(% apoptotic cells in treated sample–% apoptotic
cells in vehicle control treated sample)/(100–% apoptotic cells in vehicle control treated
sample) × 100]. Fold increase in DNA fragmentation was calculated using the following
equation: OD of drug-treated cells/OD control-treated cells.
Western Blot Analysis
5×106 cells were treated as indicated in the text. Whole cell lysates were prepared,
separated, and transferred to nitrocellulose membranes as previously described (Orlowski, et
al 2002). Antibodies against Actin, poly(ADP-ribose) polymerase (PARP) and caspase-3
(Santa Cruz Biotechnology, Inc.; Santa Cruz, CA) were used for immunoblotting.
Statistical analysis
Results were tabulated and graphed using Excel (Microsoft; Seattle, WA) and reported as
the mean ± the standard deviation (SD) for typical experiments. Each condition was
replicated in at least triplicate wells, and experiments were performed at least three times to
ensure reproducibility. Differences between experimental conditions were measured using
an unpaired student’s t-test and considered statistically significant at a p value of <0.05.
Synergistic activity of the dex/CNTO 328 combination was assessed via isobologram
analysis using Calcusyn software (Biosoft; Ferguson, MO). Combination indices (CIs) of
≤0.9 and <0.1 were considered synergistic and very strongly synergistic, respectively.
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CNTO 328 enhances dexamethasone-mediated cytoxicity in HMCLs
The viability of a panel of IL-6-dependent and –independent HMCLs grown in the presence
of 1 ng/mL of IL-6 was assessed after a 48-hour treatment with single-agent CNTO 328,
dex, or the combination, and compared to cells treated with a control antibody and vehicle.
CNTO 328 exhibited some single-agent growth inhibition in both IL-6-dependent (ANBL-6,
KAS-6/1) and –independent (H-929, MM1.S, RPMI 8226, U266) HMCLs. In the presence
of 1 ng/ml of IL-6, single-agent dex demonstrated modest activity at best, yielding
decrements in cell viability ranging from 5% (RPMI 8226) to 40% (MM1.S). In contrast,
inhibition of IL-6 with CNTO 328 sensitized most HMCLs to dex, as demonstrated by
decreases in cell viability ranging from 64% (ANBL-6) to 85% (KAS-6/1)(Figure 1A–1E).
CNTO 328 potentiated the cytotoxicity of dex to a lesser degree in U266 cells, which have
previously been shown to be resistant to GCs (Chauhan, et al 2003)(Figure 1F). To evaluate
the possibility that there was synergy between CNTO 328 and dex, isobologram analysis
was performed in ANBL-6 cells using escalating doses of each drug at a fixed 1:1 ratio. As
shown in Table 1, the combination was very strongly synergistic (CI<0.1) at all dose levels.
The proteasome inhibitor bortezomib has demonstrated notable activity in HMCLs that are
resistant to conventional myeloma therapies, including dex (Hideshima, et al 2001b). Given
the increasing use of bortezomib in relapsed/refractory and newly-diagnosed myeloma, it
was of interest to determine if the CNTO 328/dex combination was active in bortezomib-
resistant myeloma cells. To this end, a bortezomib-resistant ANBL-6 cell line, ANBL-6 BR,
was developed by incubating parental ANBL-6 cells in escalating doses of bortezomib.
After 24 hours of treatment, ANBL-6 BR cells were fully viable at bortezomib
concentrations as high as 32 nM. In contrast, the viability of parental ANBL-6 cells dropped
sharply beyond 4 nM of bortezomib (Figure 2A). ANBL-6 BR cells remained IL-6-
dependent, as demonstrated by a time- and concentration-dependent reduction in viability
with CNTO 328 treatment (Figure 2B). Notably, although single-agent CNTO 328 and dex
decreased cell viability by 48% and 24% after 48 hours of treatment, respectively, the
combination reduced viability by 84% (Figure 2C), thus demonstrating that ANBL-6 BR
cells are not cross-resistant to the CNTO 328/dex combination.
The combination of bortezomib and dex has demonstrated additive activity in pre-clinical
models of myeloma and has proven to be clinically active in newly-diagnosed and relapsed/
refractory patients (Harousseau, et al 2006, Hideshima, et al 2001b, Jagannath, et al 2005,
Jagannath, et al 2006). We therefore sought to determine whether CNTO 328 would
enhance the anti-myeloma activity of the bortezomib/dex combination. Using the WST-1
proliferation assay in ANBL-6 cells, we noted increased cytotoxicity with the three-drug
combination compared with any other one- or two-drug treatment (Figure 2D).
The role of downstream signaling pathways in IL-6-mediated GC resistance
The PI-3 kinase-Akt pathway has been implicated as a central mediator of IL-6-induced GC
resistance in the HMCL MM1.S (Hideshima, et al 2001a). To further evaluate the role of the
PI-3 kinase-Akt pathway in IL-6-mediated GC resistance, we treated ANBL-6 cells grown
in the presence of 1 ng/ml of IL-6 with the PI-3 kinase inhibitor, LY294002, dex, or the
combination for 48 hours, and evaluated their viability using the WST-1 assay. In ANBL-6
cells, although dex and LY294002 had minimal cytotoxicity as single agents, as
demonstrated by decreases in viability of only 21% and 25%, respectively, the combination
led to a 48% reduction in viability (Figure 2E). On the other hand, LY294002 had notable
single-agent activity but was not able to sensitize KAS-6/1 cells to dex, suggesting that the
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PI-3 kinase pathway does not contribute to GC resistance in all cases (Supplementary Figure
1A).
Others have previously shown that IL-6-mediated GC resistance in ANBL-6 cells strongly
correlated with the ability of IL-6 to abrogate GC-induced repression of activator protein
(AP)-1 activity (Liu, et al 1999). Given the antagonism between AP-1 and GC receptor
transcriptional activation (Jonat, et al 1990, Schule, et al 1990, Touray, et al 1991, Yang-
Yen, et al 1990), we investigated the role of the p44/42 MAPK pathway, a known modulator
of AP-1 transcriptional activity, in IL-6-mediated GC resistance. HMCLs were treated with
the MAPK kinase (MEK) inhibitor U0126, dex, or the combination and analyzed using the
WST-1 proliferation assay. Notably, treatment of ANBL-6 cells with U0126 or dex
decreased cell viability by 19% and 17%, respectively, whereas the combination reduced
viability by 66% (Figure 2F). As with LY294002, U0126 did not significantly enhance the
cytotoxicity of dex in KAS-6/1 cells (Supplementary Figure 1B).
To gain a better understanding of the relative roles of the PI-3 kinase and p44/42 MAPK
pathways in IL-6-mediated GC resistance, ANBL-6 cells were treated with varying
combinations of dex, U0126, and LY294002 with or without CNTO 328 for 48 hours and
evaluated using the WST-1 cytotoxicity assay. As shown in Supplementary Figure 1C,
although the addition of U0126 sensitized ANBL-6 cells to the cytotoxicity of dex in the
presence of IL-6, it did not confer additional cytotoxicity beyond that seen with the
combination of CNTO 328 and dex. These findings suggested that the p44/42 MAPK
pathway was important in mediating IL-6-dependent GC resistance, but did not render the
cells more susceptible to GCs in the absence of IL-6 signaling. In contrast, the addition of
LY294002 led to further cytoreduction beyond that seen with CNTO 328 and dex. The latter
data indicated that inhibition of the PI-3 kinase pathway rendered ANBL-6 cells more
innately susceptible to GC-mediated cytotoxicity in a fashion that was not totally dependent
on IL-6 signaling.
CNTO 328 potentiates dexamethasone-mediated apoptosis
To evaluate the basis for the enhanced cytotoxicity of the CNTO 328/dex combination,
ANBL-6 and KAS-6/1 HMCLs were treated with single-agent CNTO 328, dex, or the
combination for 48 hours and analyzed via cell surface Annexin-V staining. Treatment with
CNTO 328 or dex alone induced little to modest increases in apoptosis, yielding drug-
specific Annexin-V staining of 5.4% and 19.5% with CNTO 328, and 13.6% and −3.8%
with dex in ANBL-6 (Figure 3A) and KAS-6/1 cells (Figure 3B), respectively. In contrast,
drug-specific Annexin-V staining was seen in 40.2% and 60.8% of KAS-6/1 and ANBL-6
cells treated with the combination. Similarly, DNA fragmentation was enhanced in CNTO
328- and dex-treated HMCLs compared to treatment with either single agent (Figure 3C and
3D). CNTO 328 also potentiated dex-mediated activation of PARP cleavage, another marker
of programmed cell death (data not shown).
Myeloma cells become IL-6-independent in the presence of BMSCs (Chatterjee, et al 2002).
Furthermore, multiple factors present in the bone marrow microenvironment confer
myeloma GC resistance. Therefore, we investigated the activity of the CNTO 328/dex
combination in ANBL-6 and KAS-6/1 cells grown in the presence of human BMSCs
without exogenous IL-6. Importantly, although treatment of ANBL-6 and KAS-6/1 cells
with single-agent CNTO 328 or dex for 48 hours led to little or no effect on apoptosis in the
presence of BMSCs, CNTO 328 potentiated dex-mediated induction of Annexin-V staining
(Figure 3E and 3F). Thus, these results suggested that CNTO 328 enhanced the cytotoxicity
of dex by potentiating dex-mediated activation of apoptosis, both in cell suspension and the
presence of bone marrow stroma.
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To further characterize the basis for enhanced induction of apoptosis with CNTO 328 and
dex, ANBL-6 cells were treated with either drug alone, or the combination, incubated with
FITC-DEVD-FMK, a fluorescent reagent that specifically binds activated caspase-3, and
subjected to flow cytometric analysis. Although treatment with single-agent CNTO 328 and
dex led to no or minimally increased drug-specific activation of caspase-3, at 0% and 14%,
respectively, the combination dramatically enhanced caspase-3 activation to 69% (Figure
4A). Similarly, CNTO 328 potentiated dexamethasone-mediated cleavage of caspase-3 via
Western blot analysis, further confirming that the cytotoxicity of the combination was the
result of augmented activation of caspase-dependent cell death (Figure 4B). To determine
whether CNTO 328 enhanced dex-mediated induction of the extrinsic or intrinsic apoptotic
pathways, treated ANBL-6 cells were incubated with fluorogenic substrates specific for
activated caspase-8 and -9, markers of extrinsic and intrinsic pathway activation,
respectively, and analyzed by fluorometry. Even though single-agent CNTO 328 did not
activate either caspase-8 or -9, it strongly potentiated dex-mediated induction of both
caspases, thus demonstrating that CNTO 328 augments dex-mediated cell death through
activation of both the extrinsic and intrinsic apoptotic cascades (Figure 4C and 4D).
CNTO 328 potentiates the cytotoxicity of dexamethasone in patient myeloma samples
We further characterized the activity of the CNTO 328/dex combination in CD138+ plasma
cells derived from 7 patients with either newly-diagnosed or relapsed/refractory myeloma,
or plasma cell leukemia. Of note, all patients from which the samples were collected
harbored some level of clinical resistance to GCs, as evidenced by the fact that 7 out of 7
had disease which had previously not responded, or did not subsequently respond, to GC-
based therapy (Supplementary Table 1). CD138+ plasma cells were treated with CNTO 328,
dex, or the combination for 48 hours and subsequently evaluated using the WST-1
proliferation assay. Single-agent CNTO 328 exhibited varying degrees of cytotoxicity, with
reductions in cell viability ranging from −6% to 67%, thus demonstrating that there is
considerable variability of in vitro IL-6 dependence between patient samples. The in vitro
activity of single-agent dex in the presence of 1 ng/ml of IL-6 was modest in most patient
samples, with decreases in cell viability ranging from −11% to 51%. Statistically significant
decreases in cell viability with single-agent dex relative to F105/EtOH-treated controls were
only seen in 2 cases (samples 001 and 007). The combination of CNTO 328 and dex led to
greater cytotoxicity then either agent alone in most samples, with the exception of sample
005, and was significant in four out of seven (p<0.05, Table 2). Importantly, the enhanced
activity of the combination was seen in samples obtained from newly-diagnosed and
relapsed/refractory myeloma patients, those with high-risk cytogenetic features, and those
with GC-resistant disease (Supplementary Table 1).
Discussion
Although GCs are an effective class of agents for the treatment of myeloma, resistance is a
significant problem. The development of therapeutics that target known mechanisms of GC
resistance represents an attractive strategy for improving patient outcomes to GC-based
combination therapy. Herein, we show that inhibition of IL-6 with CNTO 328, a clinical
grade, monoclonal neutralizing anti-IL-6 antibody, potently sensitized HMCLs, both in
suspension and in the presence of BMSCs, as well as CD138+ plasma cells derived from
patients with myeloma, to dex-mediated cytotoxicity via potentiation of dex-induced
activation of the intrinsic and extrinsic apoptotic pathways. CNTO 328/dex was active
regardless of HMCL dependence on IL-6 for growth and survival. The combination was also
active in CD138+ plasma cells isolated from patients with documented resistance to GC-
based therapy. Notably, activity was demonstrated in a sample derived from a plasma cell
leukemia patient with documented resistance to bortezomib (sample 007, Supplementary
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Table 1), as well as a bortezomib-resistant HMCL, thus suggesting that bortezomib
resistance does not confer cross-resistance to the CNTO 328/dex combination in vitro. As
the CNTO 328/dex regimen moves into the clinic, it will be interesting to see the level of
activity in patients with documented resistance to prior GC- and bortezomib-based therapy.
One might predict that inhibition of IL-6 would be an ineffective means of overcoming GC
resistance, particularly given the growing list of factors present in the bone marrow
microenvironment that confer resistance to this class of agents. However, previous results
demonstrated that inhibition of IL-6 signaling with either anti-IL-6 antibodies or Sant7, an
antagonist that interferes with IL-6/IL-6 receptor interactions, enhanced the cytotoxicity of
dex in ANBL-6, XG-1 and INA-6 HMCLs, as well as in patient myeloma samples, even
when grown in the presence of human BMSCs (Cheung and Van Ness 2001, Grigorieva, et
al 1998, Honemann, et al 2001). Similarly, although Sant7 or dex alone did not inhibit
INA-6 cell growth in the SCID-Hu murine xenograft model of human myeloma, as assessed
by measurement of soluble IL-6 receptor levels, the combination synergistically slowed their
proliferation (Tassone, et al 2005). In our hands, while single-agent CNTO 328 and dex had
minimal apoptotic activity in the presence of stroma, the combination significantly enhanced
induction of cell death in ANBL-6 and KAS-6/1 cells. However, it should be noted that
induction of apoptosis in ANBL-6 cells treated with anti-IL-6 antibodies and dex was not as
robust when the cells were grown in the presence of stroma as opposed to cell suspension
with exogenous IL-6 (Cheung and Van Ness 2001). Furthermore, others have shown that
bone marrow stroma protected patient myeloma cells from dex-mediated cell death more
effectively than 10 ng/ml of IL-6 (Grigorieva, et al 1998). We noted a decrease in the level
of apoptosis achieved with CNTO 328/dex when ANBL-6 and KAS-6/1 cells were grown in
the presence of stroma compared with 1 ng/ml of exogenous IL-6 in cell suspension. Taken
together, the existing data and our current results demonstrate that IL-6 retains a central role
in mediating GC resistance within the bone marrow microenvironment despite the presence
of other resistance factors. Moving forward, it will be of interest to evaluate the efficacy of
dex when combined with anti-IL-6 therapeutics alone and in combination with inhibitors of
other GC resistance factors present within the bone marrow microenvironment.
Targeting of crucial signaling pathways downstream of IL-6 and other factors that mediate
GC resistance represents an attractive approach to improving the efficacy of GCs within the
bone marrow microenvironment. The PI-3 kinase-Akt pathway has been identified as an
important component of IL-6-mediated GC resistance in myeloma cells (Hideshima, et al
2001a, Ogawa, et al 2000). In support of this, our results demonstrated that treatment with
the PI-3 kinase inhibitor, LY294002, enhanced the cytotoxicity of dex in ANBL-6 cells
grown in the presence of IL-6. However, investigators have shown that the PI-3 kinase-Akt
pathway was not activated by IL-6 in all HMCLs and patient myeloma samples (Pene, et al
2002, Tu, et al 2000). Furthermore, in our hands, inhibition of PI-3 kinase only partially
reversed IL-6-mediated GC resistance in ANBL-6 cells, and was not able to overcome
resistance in KAS-6/1 cells at all. One additional pathway that has been implicated in IL-6-
mediated GC resistance is the p44/42 MAPK pathway (Ogawa, et al 2000). Our current
results also support a role for the p44/42 MAPK pathway, at least in some cases, as
treatment with the MEK inhibitor, U0126, significantly enhanced the cytotoxicity of dex in
ANBL-6 cells grown in the presence of IL-6. Similarly, others have shown that a MEK
inhibitor in clinical development, AZD6244, sensitized the IL-6-dependent HMCL, INA-6,
to dex (Tai, et al 2007). These data would suggest that multiple signaling pathways
contribute to IL-6-mediated GC resistance, and that there is likely to be significant inter-
individual variation.
Interestingly, others have shown that IL-6-mediated suppression of dex-induced apoptosis in
ANBL-6 cells was strongly associated with its ability to abrogate inhibition of AP-1 DNA
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binding by dex (Liu, et al 1999). Similarly, augmentation of T cell receptor signaling via
IL-2 or CD28 co-stimulation abrogated dex-induced suppression of CD4+ T cell
proliferation, c-Fos expression, and consequent AP-1 activity. Pre-treatment of the CD4+ T
cells with U0126 overcame IL-2/CD28-mediated GC resistance (Tsitoura and Rothman
2004). Given these results, as well as a wealth of literature documenting the antagonistic
interactions between AP-1 and the GC receptor (Jonat, et al 1990, Schule, et al 1990,
Touray, et al 1991, Yang-Yen, et al 1990), modulation of AP-1 activity may be an important
mechanism of GC resistance in myeloma. In support of this, transient transfection of a
dominant negative construct of c-Jun, a component of AP-1 complexes, into RPMI 8226
cells significantly enhanced dex-mediated cell death in the presence of IL-6 (Xu, et al 1998).
Clearly, further investigation into the role of AP-1 and upstream effectors of AP-1 activity in
growth factor-mediated GC resistance is warranted.
Numerous factors intrinsic to myeloma cells have been shown to confer GC resistance in
vitro, including activating mutations in N-Ras and K-Ras, TNF receptor-associated factor
(TRAF)-3 deletions, as well as over-expression of heat shock protein (HSP)-27 (Chauhan, et
al 2003, Keats, et al 2007, Rowley, et al 2000). In our hands, CNTO 328 was not able to
overcome GC resistance in all patient samples tested, nor in all HMCLs, further supporting
the idea that resistance is not mediated by the bone marrow microenvironment in all cases.
Furthermore, others have shown that IL-6 could only confer dex resistance in the CD45+,
immature fraction of patient malignant plasma cells, which is notable given the important
role that CD45 plays in IL-6-mediated proliferation (Fujii, et al 1999, Grigorieva, et al 1998,
Mahmoud, et al 1998). Thus, the existing pre-clinical data, as well as ours, would suggest
that there is significant inter- and intra-individual variation in GC resistance. Ultimately, it is
likely that multiple pathways of GC resistance will need to be targeted, including those
derived from the bone marrow microenvironment as well as those intrinsic to the myeloma
cells themselves, to optimally improve outcomes to GC-based therapy.
We have previously shown that CNTO 328 enhances the cytotoxicity of bortezomib in pre-
clinical models of myeloma by accelerating bortezomib-mediated activation of the extrinsic
and intrinsic apoptotic cascades (Voorhees, et al 2007). Given the increasing use of
bortezomib/dex combinations in clinical practice, we were interested in determining the
activity of bortezomib in combination with CNTO 328 and dex. Importantly, we noted
increased activity with the three-drug regimen. As such, one promising avenue for future
clinical investigation will be the incorporation of CNTO 328 into bortezomib/GC-based
therapy.
Taken together, we have shown that IL-6 is an important GC resistance factor in myeloma
that is effectively targeted by CNTO 328. Our data provide a strong rationale for the clinical
development of the CNTO 328/dex combination for patients with myeloma. To this end, an
on-going phase II clinical study of CNTO 328 and dexamethasone in relapsed/refractory
myeloma has demonstrated promising preliminary results (Voorhees, et al 2008).
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Refer to Web version on PubMed Central for supplementary material.
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HMCLs human myeloma cell lines
HSP heat shock protein
IL interleukin




PI-3 kinase phosphatidylinositol-3 kinase
PARP poly(ADP-ribose) polymerase
RAFTK related adhesion focal tyrosine kinase
SCID-Hu severe combined immunodeficiency-human hybrid
SD standard deviation
TRAF Tumor Necrosis Factor Receptor-associated factor
Also, standard single letter abbreviations for amino acids are used to indicate the sequences
of peptide-based caspase inhibitors.
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Figure 1. The activity of CNTO 328 and dexamethasone in human myeloma cell lines
ANBL-6 (A), KAS-6/1 (B), H-929 (C), MM1.S (D), RPMI 8226 (E), and U266 (F) HMCLs
were treated with 10 µg/ml of the isotype control antibody, F105 (white bars), or CNTO 328
(black bars), and either vehicle control (EtOH) or 1 µM dex for 48 hours. Cytotoxicity was
assessed via the WST-1 assay and expressed as percent cell viability relative to vehicle-
treated controls. Columns, mean of triplicate cultures; bars, SD. * = p<0.01.
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Figure 2. CNTO 328 and dexamethasone in bortezomib-resistant ANBL-6 cells and in
combination with bortezomib
(A) ANBL-6 (open circles) and ANBL-6 BR (closed triangles) HMCLs were treated with
escalating doses of bortezomib (bort) for 24 hours. (B) ANBL-6 BR cells were treated with
escalating doses of CNTO 328 for 48 (open circles) and 72 hours (closed triangles). (C)
ANBL-6 BR cells were treated with 10 µg/ml of F105 (white bars) or CNTO 328 (black
bars) and vehicle control (EtOH) or 1 µM of dex for 48 hours. (D) ANBL-6 cells were
treated with various combinations of F105 (10 µg/ml), CNTO 328 (10 µg/ml), dex (1 µM),
and bortezomib (3 nM) for 48 hours. (E, F) The impact of signaling pathways downstream
of IL-6 on glucocorticoid resistance. ANBL-6 cells were treated with vehicle control
(DMSO) or 10 µM of the PI-3 kinase inhibitor, LY294002 (D), or 20 µM of the MEK
inhibitor, U0126 (E), and EtOH or 1 µM dex for 48 hours. Cell viability for all of the above
conditions was assessed using the WST-1 cell proliferation assay. Cytotoxicity was
calculated as percent cell viability relative to vehicle-treated controls. Columns, mean of
triplicate cultures; bars, SD. * = p<0.01.
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Figure 3. CNTO 328 potentiates dexamethasone-mediated apoptosis in human myeloma cell lines
(A, B) ANBL-6 (A) and KAS-6/1 (B) cells were treated with 10 µg/ml of F105 (white bars)
or CNTO 328 (black bars) and EtOH or 1 µM of dex for 48 hours, stained with FITC-
conjugated Annexin-V and ToPro3, and subjected to flow cytometric analysis. Results are
expressed as percent drug-specific apoptosis. (C, D) ANBL-6 (C) and KAS-6/1 (D) cells
were treated with 10 µg/ml of F105 (white bars) or CNTO 328 (black bars) and EtOH or 1
µM of dex for 24 hours and evaluated using a DNA fragmentation ELISA. Results are
expressed as fold increase in apoptosis over vehicle-treated controls. Columns, mean of
triplicate cultures; bars, SD. (E, F) ANBL-6 (E) and KAS-6/1 cells (F) grown in the
presence of BMSCs and no supplemental IL-6 were treated with 10 µg/ml F105 (white bars)
or CNTO 328 (black bars) and EtOH or 1 µM dex for 48 hours, stained with FITC-
conjugated Annexin-V and ToPro3, and subjected to flow cytometric analysis. Percent drug-
specific apoptosis is indicated in each of the upper right quadrants of the dot plot. * =
p<0.05.
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Figure 4. CNTO 328 potentiates dexamethasone-mediated activation of the intrinsic and
extrinsic apoptotic cascades
(A) ANBL-6 cells were treated with 10 µg/ml F105 (white bars) or CNTO 328 (black bars)
and EtOH or 1 µM dex for 48 hours, stained with PE-conjugated Annexin-V and the
irreversible caspase-3 inhibitor, FITC-DEVD-FMK, and subjected to flow cytometric
analysis. Results are expressed as percent drug-specific induction of caspase-3. (B) Western
blot analysis of caspase-3 activation in ANBL-6 cells treated with F105 or CNTO 328 (10
µg/ml) and EtOH or dex (1 µM) for 24 hours. Actin was used as a loading control. FL=full
length, CF=cleaved fragment. (C, D) Lysates were prepared from ANBL-6 cells treated with
10 µg/ml F105 (white bars) or CNTO 328 (black bars) and EtOH or 1 µM dex for 48 hours.
30 µg of lysate were incubated with fluorogenic substrate specific for activated caspase-8
(C) or caspase-9 (D). Results are expressed as fold increase in fluorescence units over
vehicle-treated control. Columns, mean of triplicate cultures; bars, SD. * = p<0.0001. NS =
Not significant.
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Table II
In vitro percent viability of patient myeloma samples after a 48-hour treatment with CNTO 328 and
dexamethasone.
Sample No. Control (%) CNTO 328 Dex (%) CNTO 328 + Dex (%)
001 100 ± 3.5 75 ± 1.4 72 ± 4.6 17 ± 2.8*
002 100 ± 13.8 106 ± 6.0 84 ± 13.2 73 ± 4.8
003 100 ± 32.3 90 ± 17.6 68 ± 18.5 47 ± 14.3
004 100 ± 31.3 40 ± 13.9 103 ± 25.1 13 ± 4.1*
005 100 ± 15.2 106 ± 3.2 111 ± 2.5 94 ± 0.4
006 100 ± 13.0 33 ± 5.6 104 ± 11.8 11 ± 4.6*
007 100 ± 7.2 72 ± 4.8 49 ± 8.3 29 ± 8.2*
*
P < 0.05.
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